These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 12752030)
41. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Conley RR; Mahmoud R Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400 [TBL] [Abstract][Full Text] [Related]
42. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. Lee CT; Conde BJ; Mazlan M; Visanuyothin T; Wang A; Wong MM; Walker DJ; Roychowdhury SM; Wang H; Tran PV J Clin Psychiatry; 2002 Jul; 63(7):569-76. PubMed ID: 12143912 [TBL] [Abstract][Full Text] [Related]
43. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Koro CE; Fedder DO; L'Italien GJ; Weiss S; Magder LS; Kreyenbuhl J; Revicki D; Buchanan RW Arch Gen Psychiatry; 2002 Nov; 59(11):1021-6. PubMed ID: 12418935 [TBL] [Abstract][Full Text] [Related]
44. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA J Clin Psychiatry; 2002 May; 63(5):408-13. PubMed ID: 12019665 [TBL] [Abstract][Full Text] [Related]
45. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Leucht S; Pitschel-Walz G; Abraham D; Kissling W Schizophr Res; 1999 Jan; 35(1):51-68. PubMed ID: 9988841 [TBL] [Abstract][Full Text] [Related]
46. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Markianos M; Hatzimanolis J; Lykouras L Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576 [TBL] [Abstract][Full Text] [Related]
47. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine. Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994 [No Abstract] [Full Text] [Related]
48. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study. Hong J; Novick D; Brugnoli R; Karagianis J; Dossenbach M; Haro JM BMC Psychiatry; 2012 Dec; 12():218. PubMed ID: 23206324 [TBL] [Abstract][Full Text] [Related]
49. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Atmaca M; Kuloglu M; Tezcan E; Ustundag B J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665 [TBL] [Abstract][Full Text] [Related]
50. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820 [TBL] [Abstract][Full Text] [Related]
51. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics. Aguglia E; De Vanna M; Onor ML; Ferrara D Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1229-33. PubMed ID: 12502008 [TBL] [Abstract][Full Text] [Related]
53. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491 [TBL] [Abstract][Full Text] [Related]
54. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882 [TBL] [Abstract][Full Text] [Related]
55. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Kasper S Int Clin Psychopharmacol; 1998 Nov; 13(6):253-62. PubMed ID: 9861575 [TBL] [Abstract][Full Text] [Related]
56. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413 [TBL] [Abstract][Full Text] [Related]
57. Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. Labelle A; Bourget D; Boulay LJ; Ellis J; Tessier P J Clin Psychopharmacol; 2002 Dec; 22(6):545-53. PubMed ID: 12454553 [TBL] [Abstract][Full Text] [Related]
58. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255 [TBL] [Abstract][Full Text] [Related]
60. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]